Nigerian healthcare will soon receive a boost with the coming of a bioscience-accelerating healthcare system through the partnership of Sygen Pharmaceuticals and the Canadian ORx Pharmaceuticals Corp.
Unveiling the partnership, which will give birth to Sygen-ORx Biosciences Ltd, Sygen Pharmaceuticals Ltd, Lagos and ORx Pharmaceuticals Corporation, Ontario, Canada, said this joint venture will bring about innovation in the healthcare sector.
According to Chief Executive Officer, ORx Pharmaceuticals, Dr. Alexander MacGregor, the partnership, “will build upon the foundation of excellence established by ORx and Sygen, ushering in a new era of healthcare innovation.”
He said, with a shared commitment to scientific excellence and integrity, “Sygen-ORx biosciences are positioned to make a significant impact in the healthcare landscape, shaping the future of medicine for generations to come.”
On his part, Chief Executive Officer, Sygen Pharmaceutical, Charles Ogunwuyi, said: “Collaboration is at the heart of our mission at Sygen Pharmaceuticals, and we are excited to embark on this transformative journey with ORx Pharmaceuticals. Together, as Sygen ORx, we have the opportunity to amplify our impact and drive innovation in healthcare, ultimately improving the lives of patients in Africa and beyond.
“Through our partnership with ORx Pharmaceuticals, we can leverage our collective strengths to deliver meaningful solutions that address critical medical challenges and advance patient care.”
Daily Sun gathered that Sygen-ORx biosciences is aimed at revolutionising healthcare and addressing pharmaceutical drug security challenges through collaborative innovation.
ORx Pharmaceuticals, an affiliate of the Toronto Institute of Pharmaceutical Technology, North America’s premier post-graduate institute for pharmaceutical technology and research, is renowned for its commitment to advancing medical science and improving patient care, brings a wealth of expertise and patented technologies in drug development and commercialization.
ORx, the company disclosed, has consistently delivered transformative therapies across various therapeutic areas, earning recognition as a leader in the pharmaceutical industry.
It said: “Also, Sygen Pharmaceuticals, known for its pioneering spirit and dedication to scientific rigour, complements ORX’s strengths with its innovative approach to healthcare solutions. With a focus on developing high-quality medications and enhancing access to innovative treatments, Sygen has established itself as a trusted partner in driving positive change in the healthcare landscape in Nigeria.
“The joint venture between ORx and Sygen represents a powerful union of vision, expertise, and commitment to improving patient outcomes and tackling pharmaceutical drug security challenges.
“By combining resources, knowledge, and capabilities, Sygen-ORx aims to accelerate the development and commercialization of cutting-edge therapies, addressing unmet medical needs and improving healthcare access for patients worldwide.”
It further disclosed that the joint venture company will focus on development of improved formulations of generic pharmaceuticals, focusing on products with established clinical efficacy and that have already received regulatory approval and achieved substantial commercial success, advancing innovative drug discovery programs into the regional and global pharmaceutical market and reduce cost and increase access to high quality branded generic medicines in Africa.
“In addition to establishing the joint venture company, Sygen and ORx will provide support to the joint venture company leveraging their expertise gained from global drug discovery research and development and commercialization and distribution, aiming to accelerate open innovation in early-stage drug discovery,” it said.